Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Zacks Investment Research downgraded Colfax Corporation ( CFX - Snapshot Report ) to a Zacks Rank #5 (Strong Sell) on February 23, 2013.
Why the Downgrade?
The $3.97 billion worth diversified machinery company posted its financial results for the fourth quarter and year 2012 on Feb 6, 2013. Adjusted net income per share in the quarter stood at 42 cents, up 27.3% year over year and 7.7% above the Zacks Consensus Estimate of 39 cents.
Despite the beat in net earnings, poor revenue yield raised our concerns for the stock. Pro forma revenue in the quarter fell 2.1%, due primarily to a 2.5% fall in organic revenue and a negative 2.9% impact from foreign currency translation. The impact of these was partially offset by a 3.3% positive contribution from acquisitions. Adjusted operating margin in the quarter plummeted 380 basis points.
Apart from the financials for the fourth quarter, guidance for the first quarter 2013 included expectation of flat organic revenue growth and earnings per share to approximate its comparable quarter’s earnings a year-ago. Impacts from higher operating profit are likely to get offset by higher interest expense and share count.
The financial results for the quarter induced downward revisions in earnings estimates for the company. The Zacks Consensus Estimate for 2013 went down by 5.6% to $1.85 while that for 2014 decreased by 6.2% to $2.44 per share in the last 30 days. Also, for 2013 and 2014, we have an Earnings ESP (Read: Zacks Earnings ESP: A Better Method) of -0.54% and -0.82%, respectively.
Other Stocks to Consider
Other stocks to watch out for in the industry are Altra Holdings, Inc. ( AIMC - Snapshot Report ) with a Zacks Rank #1 (Strong Buy) while Metso Corp. ( MXCYY ) and Atlas Copco AB ( ATLKY ) have a Zacks Rank #2 (Buy).
Read the full on ATLKY
Read the full on MXCYY
Read the full Snapshot Report on AIMC
Read the full Snapshot Report on CFX